Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Weizhizhuo Biotechnology

Request full access

Hexaell Biotech is a biopharmaceutical company focused on severe liver disease and cell therapy

Huangpu, ChinaHealth

About Shanghai Weizhizhuo Biotechnology

Shanghai Weizhizhuo Biotechnology Co., Ltd., operating under the brand Hexaell Biotech, is a biopharmaceutical company established in 2015 with a focus on developing therapies for severe liver diseases. The company is strategically located in Shanghai, with a research and development center in Zhangjiang High-Tech Park and a production base in Jiading Industrial Park. Hexaell's establishment addresses a significant unmet medical need in China, where liver diseases are prevalent and the availability of donor livers for transplantation is critically low.

The company's core technology revolves around a cell differentiation and production platform. Its main product candidate is the HepaCure Bioartificial Liver, a liver support system that functions as a device-drug combination product. This system utilizes a proprietary cell transdifferentiation technology known as hiHeps, which converts human fibroblasts directly into functional hepatocyte-like cells. During treatment, a patient's plasma is processed through a bioreactor containing these hiHeps cells. This process aims to remove toxins from the blood, supply essential liver-specific proteins, reduce inflammation, and stimulate the regeneration of the patient's own liver. This approach offers a new therapeutic option for patients suffering from various forms of liver failure.

Hexaell has made significant progress in its development pipeline. In July 2017, the company established the first domestic production line for the clinical research and development of its human hepatocyte-derived bioartificial liver. A major milestone was achieved in December 2022, when China's National Medical Products Administration (NMPA) cleared the Investigational New Drug (IND) application for the HepaCure Biocolumn, allowing the company to proceed with clinical trials. The firm has successfully attracted venture capital to finance its operations and research. Notably, it completed a Series A funding round of ¥50 million ($7.24 million) in late 2018 and a substantial Series B+ financing of 200 million yuan in February 2025. This capital is being used to advance clinical research, scale up commercial production capabilities, and develop its pipeline of future therapies.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Industry
Health
Sector
Biotechnology, Hard Tech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Apr 2026 $15M $155M Guangdong Technology Financial Group · Fuho Capital · Shenzhen Capital Group · Cuiheng Group ↗
SERIES BOther financing Feb 2025 $31M $124M Longpan Investment · SHC Shanghai Biomedical Fund ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Weizhizhuo Biotechnology website traffic

Latest recorded traffic for Shanghai Weizhizhuo Biotechnology is 100 monthly website visits.

Latest monthly visits100
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Weizhizhuo Biotechnology in the Huangpu ecosystem

Live from Dealroom

The Shanghai Weizhizhuo Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • SHC Shanghai Biomedical Fund
  • Longpan Investment
  • Guangdong Technology Financial Group
  • Fuho Capital
  • Shenzhen Capital Group
  • Cuiheng Group
  • Zhongshan Financial
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Weizhizhuo Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Weizhizhuo Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.